Olema Pharmaceuticals News

Promising Future for Olema Pharmaceuticals With Palazestrant in Breast Cancer Treatment: A Buy Rating

TipRanksMay 2 18:27

Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge

TipRanksApr 12 23:55

Olema Pharmaceuticals Analyst Ratings

BenzingaApr 2 19:08

Goldman Sachs Initiates Coverage On Olema Pharmaceuticals With Buy Rating, Announces Price Target of $24

BenzingaApr 2 19:09

Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment

TipRanksMar 12 21:45

Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity

TipRanksMar 12 20:05

Oppenheimer Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TipRanksMar 12 20:05

Olema Pharmaceuticals Analyst Ratings

BenzingaMar 12 18:33

HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $25

BenzingaMar 12 18:39

Strong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals' Palazestrant

TipRanksMar 12 08:25

Buy Rating for Olema Pharmaceuticals' Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer Treatment

TipRanksMar 7 03:05

Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)

TipRanksFeb 22 20:54

Olema Pharmaceuticals Analyst Ratings

BenzingaJan 30 20:30

Buy Rating Justified by Olema Pharmaceuticals' Strategic Position in Breast Cancer Therapy Innovation

TipRanksDec 18, 2023 09:35

Buy Rating for Olema Pharmaceuticals Backed by Promising Clinical Data and Stable Financials

TipRanksDec 6, 2023 08:35

Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), SELLAS Life Sciences Group (SLS)

TipRanksNov 30, 2023 23:40

Buy Rating Affirmed for Olema Pharmaceuticals Amidst Upcoming Data Releases and Strategic Drug Development Progress

TipRanksNov 28, 2023 21:16

Promising Outlook for Olema Pharmaceuticals' Palazestrant: Buy Rating Backed by Robust Clinical Results and High Potential for Successful OPERA-01 Trial

TipRanksNov 8, 2023 13:15

Canaccord Genuity Adjusts Olema Pharmaceuticals' Price Target to $22 From $16, Maintains Buy Rating

MT NewswiresOct 24, 2023 22:29

Promising Prospects for Olema Pharmaceuticals: Buy Rating Justified by Palazestrant's Efficacy and Market Performance

TipRanksOct 24, 2023 18:41